Castle Biosciences to Acquire GI Health Company Previse (HIT Consultant)

Castle Biosciences has signed a definitive agreement to acquire Previse, a GI health company focused on early detection of esophageal cancer and related conditions. Founded in 2018, Previse developed Esopredict®, a sensitive epigenetic test that predicts the risk of progression in Barrett’s esophagus patients. The test is based on NIH-backed biomarker research from Johns Hopkins. This acquisition strengthens Castle’s diagnostics portfolio and expands its reach into gastroenterology, targeting a high-risk, underserved patient population.